Yimei Han

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 9

This page only lists publications with an associated author ORCID identifier.

Publications

Himani Aggarwal, KayOnda Bayo, Yimei Han, Catherine Elizabeth Muehlenbein, Yajun Emily Zhu, Jong Seok Kim
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Immunotherapy 15 (4) (2023)
Himani Aggarwal, KayOnda Bayo, Yimei Han, Catherine Elizabeth Muehlenbein, Yajun Emily Zhu, Jong Seok Kim
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Immunotherapy 15 (4) (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research (2023)
Himani Aggarwal, KayOnda Bayo, Yimei Han, Catherine Elizabeth Muehlenbein, Yajun Emily Zhu, Jong Seok Kim
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Immunotherapy 15 (4) (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)
Himani Aggarwal, KayOnda Bayo, Yimei Han, Catherine Elizabeth Muehlenbein, Yajun Emily Zhu, Jong Seok Kim
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA. Immunotherapy (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)
Himani Aggarwal, Yimei Han, Kristin M Sheffield, Zhanglin Lin Cui
Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer. Journal of comparative effectiveness research 12 (2) (2023)